Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
1(9%)
Results Posted
44%(4 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
3
27%
Ph phase_3
1
9%
Ph phase_1
2
18%
Ph phase_2
1
9%
Ph phase_4
4
36%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
4(36.4%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 21 (9.1%)
Phase 31 (9.1%)
Phase 44 (36.4%)
N/A3 (27.3%)

Trials by Status

completed982%
recruiting19%
terminated19%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11